MA
VKTX icon

MYDA Advisors’s Viking Therapeutics VKTX Stock Holding History

MYDA Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,000
Closed -$199K – 141
2019
Q1 		$199K Buy
20,000
+5,000
+33% +$41.9K 0.1% 100
2018
Q4 		$115K Buy
+15,000
New +$179K 0.2% 56

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors's VKTX Position: Q2 2019 in Review

MYDA Advisors sold out of Viking Therapeutics (VKTX) in Q2 2019, closing a stake of 50,000 shares — an estimated $497K sold.

MYDA Advisors first reported a position in VKTX in Q3 2018 and held it in 3 quarters. The position peaked at $497K in Q1 2019. 156 funds tracked by Wall St. Rank hold VKTX as of Q2 2019.

  • MYDA Advisors reported no remaining Viking Therapeutics position as of Q2 2019 after selling out during the quarter.
  • MYDA Advisors sold 50,000 Viking Therapeutics shares in Q2 2019, an estimated $497K.
  • MYDA Advisors first reported a position in Viking Therapeutics in Q3 2018 and held it in 3 quarters.
  • MYDA Advisors's Viking Therapeutics position peaked at $497K in Q1 2019.
  • 156 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2019.

Based on MYDA Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.